<DOC>
	<DOC>NCT01390220</DOC>
	<brief_summary>The purpose of this study is to examine the safety and effectiveness of USL261 for the outpatient treatment of seizure clusters.</brief_summary>
	<brief_title>Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Has a competent, adult caregiver who can recognize and observe the subject's seizure cluster episodes Has an established diagnosis of partial or generalized epilepsy that includes the following: A documented history of seizure clusters lasting a minimum of 10 minutes Seizure cluster pattern is observable, stereotyped, and recognizably different from the subject's other noncluster seizure activity (if any) A second seizure in the seizure cluster typically occurring within 6 hours from the time of cluster recognition A seizure cluster pattern composed of multiple (≥ 2) partial or generalized seizures A seizure cluster pattern established &gt; 3 months before Visit 1 A frequency of ≥ 3 seizure clusters during the year before Visit 1 At least 1 seizure cluster occurring ≤ 4 months before Visit 1 Seizure cluster pattern is confirmed by a central reviewer Currently on a stable regimen of AEDs (no changes in type of AEDs) since Visit 1 and for ≥ 7 days before Visit 2, with or without intermittent use of benzodiazepines at a constant dose Weight is 40kg to 125kg, inclusive Has a neurological disorder that is likely to progress in the next year Has severe chronic cardiorespiratory disease Has had psychogenic, nonepileptic seizure(s) within the 5 years before Visit 1 Has a history of their stereotypical seizure cluster progressing to status epilepticus within the 2 years before Visit 1 Has a history of acute narrowangle glaucoma. Has had active suicidal plan/intent or active suicidal thoughts in the 6 months before Visit 1 or a suicide attempt in the past 5 years Currently using a VNS unless the device has been implanted for at least 6 months and the setting stable for 4 weeks before Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>seizure clusters</keyword>
	<keyword>acute repetitive seizures</keyword>
	<keyword>rescue treatment</keyword>
	<keyword>ARTEMIS</keyword>
</DOC>